STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABEO
  4. [Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity

ABEONA Insider Sale: CFO Disposes 9,035 Shares After Vesting

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Joseph Walter Vazzano, Chief Financial Officer of ABEONA THERAPEUTICS INC. (ABEO), reported the sale of 9,035 shares of common stock on 09/29/2025. The disclosed weighted-average price was $5.3935 per share, with individual trade prices ranging between $5.35 and $5.46. The filing states the shares were sold to cover tax obligations arising from the vesting of restricted stock awards. After the reported sale, the reporting person beneficially owned 453,631 shares, held directly. The Form 4 reflects a routine tax-related disposition rather than a market-timing or strategic sale.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sold a small number of shares to cover taxes; ownership remains substantial, so market impact is likely minimal.

The sale of 9,035 shares at a weighted average of $5.3935 appears explicitly tax-driven tied to restricted stock vesting. Such dispositions are commonly routine and do not indicate a change in corporate outlook. The reporting person retains 453,631 shares, which maintains meaningful insider alignment with shareholders. There is no disclosure of additional planned sales or unusual trading patterns within this Form 4.

TL;DR: Transaction is a typical tax-covering sale after vesting; governance signal is neutral given continued substantial ownership.

The explanatory note clarifies the sale's purpose was to satisfy tax obligations from vesting, a common practice under equity compensation plans. Retaining 453,631 shares suggests the CFO continues to hold a sizeable position, which supports alignment with long-term shareholders. The filing contains no indication of policy changes, pledging, or other governance events.

Insider Vazzano Joseph Walter
Role Chief Financial Officer
Sold 9,035 shs ($49K)
Type Security Shares Price Value
Sale Common Stock 9,035 $5.3935 $49K
Holdings After Transaction: Common Stock — 453,631 shares (Direct)
Footnotes (1)
  1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Vazzano Joseph Walter
(Last) (First) (Middle)
6555 CARNEGIE AVE., 4TH FLOOR
(Street)
CLEVELAND OH 44103
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/29/2025 S(1) 9,035 D $5.3935(2) 453,631 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Joseph Vazzano 10/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What shares did ABEO CFO Joseph Vazzano sell?

The CFO sold 9,035 shares of ABEO common stock in transactions reported on 09/29/2025.

Why were the ABEO shares sold by the reporting person?

The Form 4 states the sale was to cover tax obligations associated with the vesting of restricted stock awards.

At what price were the ABEO shares sold?

The reported weighted-average price was $5.3935 per share, with individual trades ranging from $5.35 to $5.46.

How many ABEO shares does Joseph Vazzano own after the sale?

After the reported transaction, he beneficially owned 453,631 shares, held directly.

Does the Form 4 indicate additional insider sales or planned disposals?

No. The Form 4 discloses only the described sale to cover taxes and does not state any additional planned sales.